Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 261-267

  Hillman, Richard J ^a   Giuliano, Anna R ^b   Palefsky, Joel M ^c   Goldstone, Stephen ^d   Moreira, Edson D ^e   Vardas, Eftyhia ^f,g   Aranda, Carlos ^h   Jessen, Heiko ⁱ   Ferris, Daron G ^j   Coutlee, Francois ^k   Marshall, J Brooke ^l   Vuocolo, Scott ^l   Haupt, Richard M ^l   Guris, Dalya ^l   Garner, Elizabeth I O ^l  

^a UNIVERSITY OF SYDNEY   (Australia)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g LANCET LABORATORIES   (South Africa)

^h INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

ⁱ J2: Private Clinic for Infectious Diseases   (Germany)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXYPHOSPHATE SULFATE; IMMUNOLOGICAL ADJUVANT; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASIAN; BLOOD SAMPLING; CAUCASIAN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; HETEROSEXUAL MALE; HISPANIC; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; IMMUNOGENICITY; MALE; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEXUALITY; SMOKING; VACCINATION;

EID: 84856473763     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05208-11     Document Type: Article

References (15)

1. Castellsague X, Bosch FX, Munoz N. 2003. The male role in cervical cancer. Salud. Publica Mex. 45(Suppl. 3):S345-S353. (Pubitemid 38029651)
2. Cook IF. 2008. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 26:3551-3555.
3. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-1927.
4. Garland SM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-1943. (Pubitemid 46740303)
5. Giuliano AR, et al. 2008. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol. Biomarkers Prev. 17:2036-2043.
6. Giuliano AR, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364:401-411.
7. Moreira ED, Jr, et al. 2011. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like particle vaccine in older adolescents and young adults. Hum. Vaccin. 7:768-775.
8. Olsson S-E, et al. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 25:4931-4939. (Pubitemid 46843434)
9. Opalka D, et al. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10:108-115. (Pubitemid 36133838)
10. Palefsky JM. 2007. HPV infection in men. Dis. Markers 23:261-272. (Pubitemid 47018218)
11. Palefsky JM, et al. 2005. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19:1407-1414. (Pubitemid 41800677)
12. Reference deleted.
13. Stanberry LR, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661. (Pubitemid 35340783)
14. Villa LL, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278. (Pubitemid 40590263)
15. Woodhall S, et al. 2008. Estimation of the impact of genital warts on health-related quality of life. Sex. Transm. Infect. 84:161-166. (Pubitemid 351871484)